Biosimilar to Remicade
Expected U.S. launch in 2023.
Biosimilars may need more time to devleop in the market.
Biologic medicines could lower spending by $153 billion by 2023.
New changes are making it more difficult for generics and biosimilars to compete on formularies.
Blockbuster drug could be key to Humira’s successor.
CD20-directed antibody indicated for several cancers and other conditions.
Biosimilar guidance provides “clarity” for drug developers.
Indicated for breast cancer, and gastric or gastroesophageal junction adenocarcinoma.
Only new biosimilars and interchangeables will recieve four-letter suffixes.